UNC School of Medicine Trial Uses CAR T-Cell Therapy to Treat Lupus
A clinical trial at the University of North Carolina School of Medicine is using CAR T-cell therapy, a treatment initially developed for cancer, to treat lupus patients. The approach genetically reprograms a patient's own T-cells to target and eliminate the…
Champaign Urbana & Springfield Decatur, IL, October 15, 2026 —
A clinical trial at the University of North Carolina School of Medicine is using CAR T-cell therapy to treat patients with lupus, according to the available summary of the research. The treatment was initially developed for cancer and is now being applied in an effort to address the autoimmune disease.
The approach involves genetically reprogramming a patient’s own T-cells so they target and eliminate autoreactive B cells, which the summary identifies as causing lupus. The strategy is intended to manage the disease by directing the modified cells toward those B cells.
The summary describes the treatment as offering new hope for managing lupus, but it does not provide trial results. It does not say how many patients are participating, when the trial began, or what outcomes have been observed. Information about the treatment protocol, follow-up period, and any safety findings was also not provided.
Without those details, the available information does not establish how well the approach works or what effects it may have for patients. The trial’s findings and its status were not specified. The description therefore outlines the treatment’s rationale, rather than reporting evidence of its effectiveness or a change in clinical practice.
Story summarized from the original created by Tisha Powell on www.wandtv.com, see more information here.
Media gallery
